Electromagnetic fields
Pulsed Electromagnetic Field (PEMF)
Graded on: knee osteoarthritis pain, self-reported, short term.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The record summarized Chang et al. (2026; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 42075549) as modest self-reported benefit when its headline result is no VAS pain or total WOMAC improvement at one month, no objective function change and high risk of bias; it is now described as such. The evidence note claimed significant pain effects while Chen et al. (2019; PMID 31583420) found none. Added: the positive syntheses (Wu et al., 2018; PMID 30552258; Yang et al., 2020; PMID 32251502; Vigano et al., 2021; PMID 32508140) so the mixed picture is visible, and the 2026 double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends. sham trial null on WOMAC and function (Lau et al., PMID 41588476). The not-replicated flag, wrong for a nine-trial pool, is replaced: the problem is inconsistency. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 30552258 PMID 31583420 PMID 32251502 PMID 32508140 PMID 41588476 PMID 42075549
Every change to a letter on this site is dated and published. The full evidence log →
PEMF uses pulsing magnetic fields applied to the body. For knee arthritis pain, several reviews of studies against a fake device found short-term pain relief. Other reviews found no pain relief, or no gain in movement. Many of the studies had design weaknesses. So the evidence for knee pain is mixed.
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →Graded on Knee osteoarthritis pain, self-reported, short term.
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on knee osteoarthritis pain. Several sham-controlled meta-analyses report short-term pain benefit (Wu et al., 2018; PMID 30552258; Yang et al., 2020; PMID 32251502; Vigano et al., 2021; PMID 32508140), while others are null on pain (Chen et al., 2019; PMID 31583420) or null at one month with no objective function gain and high risk of bias (Chang et al., 2026; PMID 42075549). The newest sham-controlled trial (Lau et al., 2026; PMID 41588476), 60 patients, found no WOMAC, chair-stand or walk benefit, only knee extension torque at 6 months. Self-reported endpoints The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. with inconsistent pooled results and heterogeneous devices are C.
WHAT THIS GRADE DOES NOT COVERfracture healing, other joints, and any specific device setting, none of which the cited meta-analyses graded; function or structure of the knee, as distinct from pain, where the trials are null; and benefit lasting beyond about three weeks, which the two most recent syntheses and the newest trial did not find.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
The evidence, in fullSix papers, each linked to its PubMed record.
Chang et al. (Medicina, 2026; PMID 42075549): 9 randomized trials, 457 patients with knee osteoarthritis; no significant improvement in VAS pain or total WOMAC at one month, WOMAC pain better only at 18 to 21 days, stiffness and daily activity better only at one month, objective function unchanged, overall risk of bias high. Chen et al. (J Rehabil Med, 2019; PMID 31583420): 8 sham-controlled trials, 421 patients; function score improved, no advantage on WOMAC pain, VAS pain or stiffness. Wu et al. (BMJ Open, 2018; PMID 30552258): 12 sham-controlled trials; pain and function improved in knee and hand osteoarthritis, not cervical. Yang et al. (Phys Ther, 2020; PMID 32251502): 15 placebo-controlled trials across osteoarthritis sites; pain standardized mean difference 1.06, the strongest positive synthesis, including non-knee sites. Vigano et al. (Cartilage, 2021; PMID 32508140): 13 trials, 914 patients; short-term pain benefit against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received., activity scores not significant, not superior to other conservative therapies, effect shrinking with follow-up. Lau et al. (J Cachexia Sarcopenia Age-related loss of muscle mass and strength. Muscle, 2026; PMID 41588476): 60 patients with refractory mild to moderate knee osteoarthritis, double-blind sham-controlled, 30 minutes three times a week for 8 weeks, publicly funded; knee extension torque higher at 6 months, no difference in WOMAC, 6-m walk, 30-second chair stand, lean mass, cartilage thickness or joint space. Grade C: inconsistent pooled self-reported results, heterogeneous devices.
VAS pain scores and joint function at baseline and every 4 weeks. For bone density, use DEXA at baseline and 6 months. All device parameters (frequency, intensity, waveform, exposure time): these are not interchangeable between devices and published effects are protocol-specific.
Evidence notes: meta-analysis, randomized trial
Endpoint graded: Knee osteoarthritis pain, self-reported, short term (self_report)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Primary evidenceSix papers, each linked to its PubMed record.
Chang et al. (Medicina, 2026; PMID 42075549): 9 randomized trials, 457 patients with knee osteoarthritis; no significant improvement in VAS pain or total WOMAC at one month, WOMAC pain better only at 18 to 21 days, stiffness and daily activity better only at one month, objective function unchanged, overall risk of bias high. Chen et al. (J Rehabil Med, 2019; PMID 31583420): 8 sham-controlled trials, 421 patients; function score improved, no advantage on WOMAC pain, VAS pain or stiffness. Wu et al. (BMJ Open, 2018; PMID 30552258): 12 sham-controlled trials; pain and function improved in knee and hand osteoarthritis, not cervical. Yang et al. (Phys Ther, 2020; PMID 32251502): 15 placebo-controlled trials across osteoarthritis sites; pain standardized mean difference 1.06, the strongest positive synthesis, including non-knee sites. Vigano et al. (Cartilage, 2021; PMID 32508140): 13 trials, 914 patients; short-term pain benefit against placebo, activity scores not significant, not superior to other conservative therapies, effect shrinking with follow-up. Lau et al. (J Cachexia Sarcopenia Muscle, 2026; PMID 41588476): 60 patients with refractory mild to moderate knee osteoarthritis, double-blind sham-controlled, 30 minutes three times a week for 8 weeks, publicly funded; knee extension torque higher at 6 months, no difference in WOMAC, 6-m walk, 30-second chair stand, lean mass, cartilage thickness or joint space. Grade C: inconsistent pooled self-reported results, heterogeneous devices.
Products carry no letter. The letter belongs to the therapy as the trials studied it, and no trial tested these products unless the entry says so. Listed alphabetically; payment does not affect order.
Mat-based PEMF system. The manufacturer's microcirculation data is company-funded and uses proprietary endpoints, which cannot be independently checked. EBL grades the PEMF modality, not the brand: see the modality grade above, where meta-analysis doubts the clinical meaningfulness of the pain effect in knee osteoarthritis.
Portable, wearable PEMF with programmable frequencies. Sleep, cognitive, and pain programs. Battery-powered for travel use. Parameters are adjustable, important for matching study protocols.
PEMF device marketed for recovery and performance, using a proprietary, patent-pending waveform. The manufacturer publishes a frequency range but no field strength.
High-intensity PEMF system used in clinical wellness settings. Full-body mat and applicator options. Higher field strength than most consumer devices.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →